Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone408-720-9002
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$34.56 million
Profitability
Miscellaneous
Employees176
Next Earnings Date10/29/2019 (Confirmed)
OptionableNot Optionable
Silk Road Medical (NASDAQ:SILK) Frequently Asked Questions
What is Silk Road Medical's stock symbol?
Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."
How were Silk Road Medical's earnings last quarter?
Silk Road Medical Inc (NASDAQ:SILK) announced its quarterly earnings data on Monday, July, 29th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.14. The firm earned $14.93 million during the quarter, compared to the consensus estimate of $13.64 million. The company's revenue for the quarter was up 92.2% on a year-over-year basis. View Silk Road Medical's Earnings History.
When is Silk Road Medical's next earnings date?
How can I listen to Silk Road Medical's earnings call?
Silk Road Medical will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Silk Road Medical issued on next quarter's earnings?
Silk Road Medical issued an update on its FY 2019 earnings guidance on Monday, July, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60-62 million, compared to the consensus revenue estimate of $60.17 million.
What price target have analysts set for SILK?
5 brokers have issued twelve-month price objectives for Silk Road Medical's stock. Their forecasts range from $40.01 to $52.00. On average, they expect Silk Road Medical's stock price to reach $44.80 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price. View Analyst Price Targets for Silk Road Medical.
What is the consensus analysts' recommendation for Silk Road Medical?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silk Road Medical.
Has Silk Road Medical been receiving favorable news coverage?
Media headlines about SILK stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Silk Road Medical earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Silk Road Medical.
Are investors shorting Silk Road Medical?
Silk Road Medical saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,320,000 shares, an increase of 58.9% from the August 30th total of 1,460,000 shares. Based on an average trading volume of 306,800 shares, the short-interest ratio is presently 7.6 days. Currently, 14.3% of the company's shares are short sold. View Silk Road Medical's Current Options Chain.
Who are some of Silk Road Medical's key competitors?
Some companies that are related to Silk Road Medical include Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Cardiovascular Systems (CSII), Atrion (ATRI), Inspire Medical Systems (INSP), AtriCure (ATRC), Orthofix Medical (OFIX), Shockwave Medical (SWAV) and Tactile Systems Technology (TCMD).
What other stocks do shareholders of Silk Road Medical own?
Who are Silk Road Medical's key executives?
Silk Road Medical's management team includes the folowing people:
- Ms. Erica J. Rogers, Chief Exec. Officer, Pres & Director (Age 55)
- Mr. Lucas W. Buchanan, Chief Financial Officer (Age 41)
- Mr. Robert A. Nicholas, VP of Operations & Engineering (Age 56)
- Mr. Andrew S. Davis, Exec. VP of Global Sales & Marketing (Age 50)
- Ms. Alison Highlander, VP of HR
When did Silk Road Medical IPO?
(SILK) raised $75 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.
When did Silk Road Medical's lock-up period expire?
Silk Road Medical's lock-up period expired on Tuesday, October 1st. Silk Road Medical had issued 6,000,000 shares in its IPO on April 4th. The total size of the offering was $120,000,000 based on an initial share price of $20.00. Since the end of Silk Road Medical's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Who are Silk Road Medical's major shareholders?
Silk Road Medical's stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.41%) and Coastal Investment Advisors Inc. (0.02%). Company insiders that own Silk Road Medical stock include Pincus & Co Warburg and X Finance LP Wp. View Institutional Ownership Trends for Silk Road Medical.
Which major investors are buying Silk Road Medical stock?
How do I buy shares of Silk Road Medical?
Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Silk Road Medical's stock price today?
One share of SILK stock can currently be purchased for approximately $34.20.
How big of a company is Silk Road Medical?
What is Silk Road Medical's official website?
How can I contact Silk Road Medical?
Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at 408-720-9002 or via email at [email protected]
MarketBeat Community Rating for Silk Road Medical (NASDAQ SILK)
MarketBeat's community ratings are surveys of what our community members think about Silk Road Medical and other stocks. Vote "Outperform" if you believe SILK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SILK will underperform the S&P 500 over the long term. You may vote once every thirty days.
